ASH 2010
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2010 — study authors and key opinion leaders discuss the findings and their clinical implications.
Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma
ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology ann
“Obligate Radiotherapy” Makes Stanford V Less Favourable Than ABVD Chemotherapy For Hodgkin’s Disease
ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of t
Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma
ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology ann
Lenalidomide After Autologous Transplantation Delays Myeloma Progression
ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study rep
Large Cell Lymphoma: Immuno-Chemotherapy Without Radiotherapy Cures Patients With Large B Cell Lymphoma
ORLANDO—Primary mediastinal large B cell lymphoma responded excellently to a dose-dense schedule of R-CHOP immuno-chemotherapy followed by ICE chemotherapy — without the need for radiotherapy — in a s